Mindset Pharma Presents Poster at Neuroscience 2022 Highlighting Preclinical Data on MSP-1014, its Psilocybin-like Lead Drug Candidate
14. November 2022 07:30 ET
|
Mindset Pharma Inc.
TORONTO, Nov. 14, 2022 (GLOBE NEWSWIRE) -- Mindset Pharma Inc. (CSE: MSET) (FSE: 9DF) (OTCQB: MSSTF) ("Mindset" or the "Company"), a drug discovery company developing novel, optimized,...
Mindset Pharma Announces Poster Presentations at Two Upcoming Scientific Conferences
27. Oktober 2022 08:00 ET
|
Mindset Pharma Inc.
5th Annual Neuropsychiatric & Psychedelics Drug Development Summit in Boston, MA on October 31st Neuroscience 2022 by the Society of Neuroscience in San Diego, CA on November 13th TORONTO, Oct. ...
Mindset Pharma Selects Lead Clinical Candidates From “Family 2” of its Next Generation Psychedelic Drug Portfolio
05. Oktober 2022 07:00 ET
|
Mindset Pharma Inc.
TORONTO, Oct. 05, 2022 (GLOBE NEWSWIRE) -- Mindset Pharma Inc. (CSE: MSET) (FSE: 9DF) (OTCQB: MSSTF) (“Mindset” or the “Company”), a drug discovery company developing novel, optimized,...
Mindset Pharma Provides Strategic Intellectual Property License to Cybin
27. September 2022 07:30 ET
|
Mindset Pharma Inc.
TORONTO, Sept. 27, 2022 (GLOBE NEWSWIRE) -- Mindset Pharma Inc. (CSE: MSET) (FSE: 9DF) (OTCQB: MSSTF) (“Mindset”), a drug discovery company developing novel, optimized, next-generation psychedelic...
Mindset Pharma Receives Scientific Advice from UK Regulator Facilitating Advancement of Phase 1 First-In-Human Clinical Trial Plan for Its Lead Clinical Candidate, MSP-1014
14. September 2022 08:00 ET
|
Mindset Pharma Inc.
TORONTO, Sept. 14, 2022 (GLOBE NEWSWIRE) -- Mindset Pharma Inc. (CSE: MSET) (FSE: 9DF) (OTCQB: MSSTF) (“Mindset” or the “Company”), a drug discovery company developing novel, optimized,...
Mindset Pharma Files National Patents Protecting Family 1 Application in 16 Different Countries
07. September 2022 08:00 ET
|
Mindset Pharma Inc.
TORONTO, Sept. 07, 2022 (GLOBE NEWSWIRE) -- Mindset Pharma Inc. (CSE: MSET) (FSE: 9DF) (OTCQB: MSSTF) ("Mindset" or the "Company"), a drug discovery and development company focused on creating...
Mindset Pharma Further Expands its IP Portfolio with Three Additional Non-Tryptamine Families of Next-Generation Psychedelic Compounds
31. August 2022 08:00 ET
|
Mindset Pharma Inc.
TORONTO, Aug. 31, 2022 (GLOBE NEWSWIRE) -- Mindset Pharma Inc. (CSE: MSET) (FSE: 9DF) (OTCQB: MSSTF) (“Mindset” or the “Company”), a drug discovery and development company focused on creating novel,...
Mindset Pharma to Participate in the H.C. Wainwright 24th Annual Global Investment Conference on September 12-14, 2022
30. August 2022 08:00 ET
|
Mindset Pharma Inc.
TORONTO, Aug. 30, 2022 (GLOBE NEWSWIRE) -- Mindset Pharma Inc. (CSE: MSET) (FSE: 9DF) (OTCQB: MSSTF) ("Mindset" or the "Company"), a drug discovery and development company focused on creating novel,...
Mindset Pharma CEO, James Lanthier, Issues Letter to Shareholders
09. August 2022 08:00 ET
|
Mindset Pharma Inc.
TORONTO, Aug. 09, 2022 (GLOBE NEWSWIRE) -- Mindset Pharma Inc. (CSE: MSET) (FSE: 9DF) (OTCQB: MSSTF) (“Mindset” or the “Company”), a drug discovery and development company focused on creating novel,...
Mindset Pharma Receives Allowance for Patent Application Covering its Short-Duration Novel Psychedelic Medications for The Treatment of Central Nervous System Disorders
06. Juli 2022 07:30 ET
|
Mindset Pharma Inc.
TORONTO, July 06, 2022 (GLOBE NEWSWIRE) -- Mindset Pharma Inc. (CSE: MSET) (FSE: 9DF) (OTCQB: MSSTF) ("Mindset" or the "Company"), a drug discovery and development company focused on creating...